Legal Opinion
Eli Lilly and Company v. Teva Parenteral Medicines
Court of Appeals for the Federal Circuit
Decided January 12, 2017No. 2015-2067PublishedCited by 66 opinions
1Opinion of the Court
PROST, Chief Judge.
Eli Lilly & Co. (“Eli Lilly”) is the owner of U.S. Patent No. 7,772,209 (“ ’209 patent”). It fried this consolidated Hatch-Wax-man suit against Teva Parenteral Medicines, Inc.; APP Pharmaceuticals LLC; Pliva Hrvatska D.O.O.; Teva Pharmaceuticals USA, Inc.; and Barr Laboratories, Inc. (collectively, “Defendants”) to prevent Defendants from launching a generic version of a chemotherapy drug with accompanying product literature that would allegedly infringe methods of treatment claimed by the ’209 patent. The United States District Court for the Southern District of Indiana…
2Cases cited24 opinions
- KSR International Co. v. Teleflex Inc.Supreme Court of the United States · 2007
- Nautilus, Inc. v. Biosig Instruments, Inc.Supreme Court of the United States · 2014
- Dsu Medical Corporation v. Jms Co., LtdCourt of Appeals for the Federal Circuit · 2006
- Datamize, L.L.C. v. Plumtree Software, Inc.Court of Appeals for the Federal Circuit · 2005
- Teva Pharmaceuticals USA, Inc. v. Sandoz, Inc.Court of Appeals for the Federal Circuit · 2015
19 more not listed; retrieve them via the Exa API.
3Cited by66 opinions
- Vanda Pharmaceuticals Inc. v. West-Ward PharmaceuticalsCourt of Appeals for the Federal Circuit · 2018
- Eli Lilly and Company v. Hospira, Inc.Court of Appeals for the Federal Circuit · 2019
- Barry v. Medtronic, Inc.Court of Appeals for the Federal Circuit · 2019
- Sanofi v. Watson Laboratories Inc.Court of Appeals for the Federal Circuit · 2017
- Travel Sentry, Inc. v. David TroppCourt of Appeals for the Federal Circuit · 2017
61 more not listed; retrieve them via the Exa API.